Brain-derived neurotrophic factor and subcallosal deep brain stimulation for refractory depression

Area of Science:

• Neuroscience
• Psychiatry
• Biomarker Research

Background:

• Treatment-resistant depression (TRD) remains a significant clinical challenge.
• Subcallosal cingulate (SCC) deep brain stimulation (DBS) is an experimental therapy for TRD.
• Brain-derived neurotrophic factor (BDNF) plays a role in neuroplasticity and antidepressant effects.

Purpose of the Study:

• To investigate the impact of SCC-DBS on serum BDNF levels in patients with TRD.
• To explore the potential relationship between BDNF levels and clinical response to SCC-DBS.

Main Methods:

• Four TRD patients received SCC-DBS treatment.
• A 3-month double-blind optimization phase was followed by 6 months of open-label stimulation.
• Depressive symptoms were assessed using the Hamilton Depression Rating Scale (HDRS).
• Serum BDNF levels were measured pre-surgery and 9-12 months post-surgery.

Main Results:

• Three out of four patients showed clinical improvement in depressive symptoms.
• Two patients achieved a full response (≥50% HDRS reduction), and one had a partial response (35% HDRS reduction).
• All four patients exhibited a decrease in serum BDNF concentration from baseline.

Conclusions:

• SCC-DBS for TRD may be linked to reduced serum BDNF levels.
• BDNF may serve as a potential biomarker for SCC-DBS efficacy in TRD.
• Further longitudinal studies with larger sample sizes are needed to confirm these findings.